Literature DB >> 25082629

An electrophysiological classification associated with Guillain-Barré syndrome outcomes.

Takafumi Hosokawa1, Hideto Nakajima, Kiichi Unoda, Kazushi Yamane, Yoshimitsu Doi, Shimon Ishida, Fumiharu Kimura, Toshiaki Hanafusa.   

Abstract

Guillain-Barré syndrome (GBS) is an acute, post-infectious, inflammatory, autoimmune peripheral neuropathy with a highly diverse clinical course and outcome. We classified GBS on the basis of patients' first nerve conduction and validated this system to be associated with outcome on the basis of electrophysiological characteristics during the acute phase of GBS. We retrospectively evaluated 40 GBS patients who underwent their first electrophysiological study within 14 days of onset and classified GBS into four patterns: (1) acute inflammatory demyelinating polyneuropathy (AIDP) pattern with sensory nerve conduction abnormalities (motor-sensory AIDP: MS-AIDP), (2) AIDP pattern without sensory nerve conduction abnormalities (motor AIDP: M-AIDP), (3) acute motor axonal neuropathy (AMAN) pattern, and (4) minor abnormalities pattern. We compared the clinical, electrophysiological, and laboratory findings between groups and determined subgroups associated with poor outcome. The MS-AIDP and AMAN patterns more frequently exhibited prolonged recovery compared with the M-AIDP and minor abnormalities patterns and were associated with prolonged recovery (specificity, 100%; sensitivity, 73%; P < 0.001). The period of inability to walk independently was significantly longer in the MS-AIDP and AMAN patterns than in the M-AIDP and minor abnormalities patterns (median 85 vs. 10 days; P < 0.001). In conclusion, our classification of GBS using a single nerve conduction study in the early phase of disease is associated with outcomes. This classification can be used to counsel individual patients and guide decision-making with respect to treatment.

Entities:  

Mesh:

Year:  2014        PMID: 25082629     DOI: 10.1007/s00415-014-7452-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  41 in total

1.  Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan.

Authors:  K Ogawara; S Kuwabara; M Mori; T Hattori; M Koga; N Yuki
Journal:  Ann Neurol       Date:  2000-10       Impact factor: 10.422

2.  Guidelines in electrodiagnostic medicine. Consensus criteria for the diagnosis of partial conduction block.

Authors:  R K Olney
Journal:  Muscle Nerve Suppl       Date:  1999

Review 3.  Assessment of current diagnostic criteria for Guillain-Barré syndrome.

Authors:  A K Asbury; D R Cornblath
Journal:  Ann Neurol       Date:  1990       Impact factor: 10.422

4.  The prognosis and main prognostic indicators of Guillain-Barré syndrome. A multicentre prospective study of 297 patients. The Italian Guillain-Barré Study Group.

Authors: 
Journal:  Brain       Date:  1996-12       Impact factor: 13.501

5.  Recovery from acute demyelinating conduction block in the presence of prolonged distal conduction delay due to peripheral nerve constriction.

Authors:  M Baba; M Matsunaga
Journal:  Electromyogr Clin Neurophysiol       Date:  1984 Nov-Dec

6.  Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study Group.

Authors:  L H Visser; P I Schmitz; J Meulstee; P A van Doorn; F G van der Meché
Journal:  Neurology       Date:  1999-08-11       Impact factor: 9.910

Review 7.  Antibodies against ganglioside complexes in Guillain-Barré syndrome and related disorders.

Authors:  Susumu Kusunoki; Ken-ichi Kaida
Journal:  J Neurochem       Date:  2011-01-07       Impact factor: 5.372

8.  Conduction block in acute motor axonal neuropathy.

Authors:  Norito Kokubun; Momoka Nishibayashi; Antonino Uncini; Masaaki Odaka; Koichi Hirata; Nobuhiro Yuki
Journal:  Brain       Date:  2010-09-20       Impact factor: 13.501

Review 9.  Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes.

Authors:  N Yuki
Journal:  Lancet Infect Dis       Date:  2001-08       Impact factor: 25.071

10.  An acute axonal form of Guillain-Barré polyneuropathy.

Authors:  T E Feasby; J J Gilbert; W F Brown; C F Bolton; A F Hahn; W F Koopman; D W Zochodne
Journal:  Brain       Date:  1986-12       Impact factor: 13.501

View more
  4 in total

1.  Serial electrophysiological findings in Guillain-Barré syndrome not fulfilling AIDP or AMAN criteria.

Authors:  Takafumi Hosokawa; Hideto Nakajima; Kiichi Unoda; Kazushi Yamane; Yoshimitsu Doi; Shimon Ishida; Fumiharu Kimura; Toshiaki Hanafusa
Journal:  J Neurol       Date:  2016-06-08       Impact factor: 4.849

Review 2.  New evidence for secondary axonal degeneration in demyelinating neuropathies.

Authors:  Kathryn R Moss; Taylor S Bopp; Anna E Johnson; Ahmet Höke
Journal:  Neurosci Lett       Date:  2020-12-24       Impact factor: 3.046

3.  Very low peroneal nerve compound muscle action potential amplitude predicts poor outcome in patients with Guillain-Barré syndrome: a prospective cohort.

Authors:  Juan Carlos López-Hernández; Javier Andrés Galnares-Olalde; Adib Jorge de Saráchaga; María Eugenia Briseño-Godínez; Esther Pérez-Valdez; Raúl Nathanael May-Mas; José Luis Arista-Ramírez; Lisette Bazán-Rodríguez; Elizabeth León-Manriquez; Jorge Burgos-Centeno; Edwin Steven Vargas-Cañas
Journal:  Neurol Sci       Date:  2022-01-24       Impact factor: 3.307

4.  Clinical features of Guillain-Barré syndrome patients with elevated serum creatine kinase levels.

Authors:  Takafumi Hosokawa; Hideto Nakajima; Taiki Sawai; Yoshitsugu Nakamura; Eri Sano; Akihiro Tsukahara; Kiichi Unoda; Shimon Ishida; Sadaki Sakane; Fumiharu Kimura; Shigeki Arawaka
Journal:  BMC Neurol       Date:  2020-05-27       Impact factor: 2.474

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.